G-BA decisions from 4 July 2024

Here are the G-BA decisions from the G-BA meeting held on 4 July 2024 on the early benefit assessments of Agamree, Loargys, Elrexfio, Evkeeza, and Ondexxya.

A complete database of all previous G-BA resolutions is available upon request.

  • ​​​Agamree (vamorolone); Duchenne muscular dystrophy, ≥ 4 years – Orphan drug, Hint of not-quantifiable additional benefit
  • Loargys (pegzilarginase); hyperargininemia (ARG1-D), ≥ 2 years – Orphan drug, Hint of not-quantifiable additional benefit
  • Elrexfio (elranatamab); multiple myeloma, at least 3 previous therapies – Additional benefit not proven in both subgroups
  • Evkeeza (evinacumab)
  • Ondexxya (andexanet alfa); reversal of anticoagulation after treatment with apixaban or rivaroxaban due to life-threatening or uncontrollable bleeding) – Time restriction of previous decision extended to 1 July 2025

Follow me on Instagram to never miss the latest G-BA decisions:

Want my free guide about German HTA?

X